Ark Therapeutics gains wound care footwear
This article was originally published in Clinica
Executive Summary
London, UK-based specialist healthcare group Ark Therapeutics has secured exclusive UK and international marketing rights to a medical footwear device developed by German surgical, trauma and woundcare specialist, Darco, for managing diabetic foot ulcers. Under the terms of the agreement, Darco will manufacture and supply the product to Ark, which, in turn, will be responsible for reimbursement and sales and marketing. The device, to be marketed as Kerraped, is already approved for reimbursement by the UK National Health Service.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.